GlassScriptPhysician profile
Erin Mccann
NPI 1790326064
$7,818.48
in general payments reported to CMS, 2019-2025
28 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $962 · 2022: $1,682 · 2023: $2,232 · 2024: $1,940 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,175.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,668.48 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $793.89 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $702.02 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $603.56 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $448.62 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $436.68 | 2021-2025 | Trintellix |
| Alkermes, INC. | $406.84 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $393.05 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $329.47 | 2023-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $310.46 | 2021-2025 | Wellbutrin, Aplenzin |
| Neurocrine Biosciences, INC. | $246.86 | 2022-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $213.65 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $195.17 | 2021-2022 | |
| Corium, LLC | $191.62 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $141.73 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $99.62 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $93.94 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $86.56 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $84.76 | 2021-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $75.89 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $57.92 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, LP | $55.98 | 2023-2024 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $39.05 | 2021 | |
| Eisai INC. | $37.02 | 2021 | |
| Tris Pharma INC | $36.31 | 2024-2025 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $26.76 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.07 | 2025 | Rejoyn |
| Vertical Pharmaceuticals, LLC | $20.50 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.